Aadi Bioscience Plans To Adjust Ongoing Phase 2 Trials And Reduce R&D Headcount By 80%, Thereby Extending Cash Runway Into At Least 2H 2026
Portfolio Pulse from Benzinga Newsdesk
Aadi Bioscience is planning to adjust its ongoing Phase 2 trials and significantly reduce its R&D headcount by 80%. This strategic move is aimed at extending the company's cash runway into at least the second half of 2026.
August 20, 2024 | 9:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aadi Bioscience is making strategic adjustments to its Phase 2 trials and reducing its R&D workforce by 80% to extend its cash runway into at least the second half of 2026.
The decision to reduce R&D headcount and adjust trials is a significant cost-saving measure, which is likely to positively impact Aadi Bioscience's financial stability and extend its cash runway. This strategic move may be viewed favorably by investors as it demonstrates proactive financial management.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100